By Scott Kanowsky
Investing.com -- Shares in Eli Lilly and Company (NYSE:LLY) dipped in early trading on Friday after the U.S. Food and Drug Administration decided not to give early approval to the drugmaker's experimental Alzheimer's treatment.
In a statement released on Thursday, the FDA said it could not sign off on the drug - known as donanemab - because Lilly had not submitted sufficient trial data from patients who had been exposed to it for at least 12 months.
Many patients with early-stage Alzheimer's were able to stop dosing after only 6 months, Lilly said, because donanemab had effectively removed amyloid protein plaques from their brains. This resulted in fewer than 100 patients receiving 12 months of donanemab, Lilly explained.
The company added that the FDA had sent it a letter that detailed its concerns and explained how Lilly could meet the standards needed for donanemab to be approved. The FDA can give so-called "accelerated" approval to drugs that display proof of having had an impact on patient conditions.
According to Lilly, the decision will not result in a change to the group's 2023 financial guidance.
Analysts at Cantor Fitzgerald said they remained positive on donanemab given that the confirmatory trials of the drug remain ongoing. They acknowledged that many Wall Street analysts had predicted the drug would receive accelerated approval, but described the FDA's rejection as only a "near-term setback."
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.